Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New Strong Sell Stocks for July 31st

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Creative Medical Technology Holdings, Inc. CELZ is a commercial-stage biotechnology company. The Zacks Consensus Estimate for its...

WHR : 77.64 (-1.16%)
GRFS : 9.14 (-0.22%)
CELZ : 2.15 (-2.71%)
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

ADMA Biologics ADMA and Grifols GRFS are leading producers of plasma-derived therapies, specializing in immunoglobulin treatments for immunodeficiencies and other conditions.ADMA Biologics markets plasma-derived...

GRFS : 9.14 (-0.22%)
ADMA : 19.78 (-2.94%)
Grifols Stock Declines After Brookfield Drops Buyout Offer

Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a...

CTMX : 4.19 (+3.20%)
CSTL : 38.63 (+1.74%)
GRFS : 9.14 (-0.22%)
SPRO : 2.32 (-1.28%)
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 4.19 (+3.20%)
CSTL : 38.63 (+1.74%)
GRFS : 9.14 (-0.22%)
SPRO : 2.32 (-1.28%)
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain

/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...

GRFS : 9.14 (-0.22%)
Why Shares of Grifols Were Up Tuesday

The company gave first-quarter numbers.

GRFS : 9.14 (-0.22%)
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...

GRFS : 9.14 (-0.22%)
GRF : 11.50 (+6.28%)
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease

/PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research,...

GRFS : 9.14 (-0.22%)
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is...

GRFS : 9.14 (-0.22%)
GRF : 11.50 (+6.28%)
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...

GRFS : 9.14 (-0.22%)
GRF : 11.50 (+6.28%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar